The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human CX3CL1.
sELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human CX3CL1.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant human CX3CL1 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 42 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
The soluble form is chemotactic for T-cells and monocytes, but not for neutrophils. The membrane-bound form promotes adhesion of those leukocytes to endothelial cells. May play a role in regulating leukocyte adhesion and migration processes at the endothelium. Binds to CX3CR1.
Small intestine, colon, testis, prostate, heart, brain, lung, skeletal muscle, kidney and pancreas.
Belongs to the intercrine delta family.
A soluble short 95 kDa form may be released by proteolytic cleavage from the long membrane-anchored form. O-glycosylated with core 1 or possibly core 8 glycans.